Table of Contents
New research reveals that access to specialized treatment for acute lymphoblastic leukemia (ALL) is more significantly impacted by insurance status and social support than by how far patients live from cancer centers.
For adolescents and young adults (AYAs) battling acute lymphoblastic leukemia (ALL), the path to high-quality care is often riddled with obstacles that extend beyond mere distance. According to new findings presented at the 2025 American Society of Hematology annual meeting in Orlando, Florida, financial and social determinants of health pose steeper barriers than geographic limitations. These insights underscore the urgent need for policy changes and support systems to ensure equitable access to life-saving treatment.
Insurance Coverage: A Critical Determinant of Care
Researchers found that insurance status is a more consistent predictor of access to specialized cancer centers (SCCs) than travel time. A study evaluating the experiences of 4,211 newly diagnosed AYAs with ALL in California, New York, and Texas revealed a stark disparity. While it is recommended that ALL patients receive treatment at SCCs, less than half of those under 18 actually do.
The data showed that 54.5% of AYAs were treated at an SCC overall, but this figure dropped significantly in Texas, where only 27.3% received care at a specialized center, compared to 61.5% in California and 60.9% in New York. Notably, 17.8% of patients in Texas were uninsured, a rate far exceeding the 2.7% in California and 4.0% in New York. “Being uninsured was significantly associated with lower odds of being treated at an SCC,” researchers concluded.
While travel time did play a role in New York – further distances reduced the likelihood of receiving care at an SCC – it was not a significant factor in California or Texas. In Texas, despite a greater proportion of patients living more than 60 minutes from an SCC (31.8% versus 19.8% in California and 19.0% in New York), the primary barrier remained lack of insurance. “Therefore, health policies that have the potential to further reduce insurance access will worsen outcomes for this patient population,” a senior researcher stated.
The challenges extend beyond insurance coverage. A separate study highlighted the critical role of social support in mitigating the hardships faced by families of children with leukemia. Researchers analyzing data from the Children’s Oncology Group trial AALL1731 found that a lack of social support significantly increased the likelihood of household material hardship, such as food or housing insecurity.
The study, which included 1,487 parents or guardians of children ages 1 to 9 undergoing treatment for standard-risk B-cell ALL, revealed that participants with inadequate social support had 4.1 times higher odds of experiencing material hardship. Even after adjusting for other factors, inadequate social support remained a strong predictor of financial strain. The majority of participants (76%) were mothers, and 81% preferred English as their primary language. The study population was diverse, with 52% identifying as non-Hispanic White, 25% as Hispanic, and 7% as Black.
“These data identify social support as a potential target for interventions to improve parent and child wellbeing,” the researchers wrote. They plan to further investigate whether bolstering social support can also protect against financial toxicity and psychological distress during treatment. .
These findings emphasize that addressing the social determinants of health is crucial for improving outcomes for AYAs and families affected by ALL. Beyond ensuring access to specialized medical care, a holistic approach that prioritizes financial stability and social support networks is essential to navigate the complexities of this challenging illness.